Instalab
logoInstalab

Dust Mite (D. Farinae) IgE

The clearest blood signal of dust mite allergy, often the hidden driver behind year-round congestion, asthma, and eczema.

Should you take a Dust Mite (D. Farinae) IgE test?

This test is most useful if any of these apply to you.

Stuffed Up Year-Round
If your nose runs and your eyes itch every season, this test can show whether dust mites are the hidden trigger behind it all.
Living With Asthma
Dust mite is one of the strongest indoor triggers of asthma; this test reveals whether avoiding it could reduce your flare-ups.
Battling Eczema That Will Not Settle
In moderate to severe eczema, dust mite sensitization often drives the inflammation; testing helps identify a treatable trigger.
Considering Allergy Shots
A baseline level helps your allergist decide whether immunotherapy is right for you and tracks how well it is working over time.

About Dust Mite (D. Farinae) IgE

If you wake up congested most mornings, get itchy eyes when you make the bed, or have eczema and asthma that never quite settle, dust mites are one of the first culprits to rule in or out. Specifically, the American house dust mite, Dermatophagoides farinae, is one of the two species that drive most year-round indoor allergy in homes worldwide.

This test measures D. farinae IgE (immunoglobulin E), the antibody your immune system has built specifically against dust mite proteins. A positive result tells you your body is primed to react to dust mites in your bedding, carpets, and upholstery, and helps explain symptoms that a basic checkup or general inflammation marker cannot.

What This Test Actually Measures

IgE is a type of antibody made by your B cells (a kind of immune cell). When your immune system decides a harmless protein, like one from a dust mite, is dangerous, it produces IgE that locks onto that specific allergen. The next time you breathe in or touch the allergen, those antibodies trigger the release of histamine and other chemicals that cause sneezing, itching, wheezing, or rashes.

This test reads the level of IgE in your blood that targets D. farinae proteins specifically. The two main proteins driving most reactions are called Der f 1 and Der f 2. In Korean dust mite allergy patients, about 79% had IgE against each of these, and combining the two captured 88 to 92% of people with mite-driven respiratory allergy. Across countries, group 1 and 2 allergens are the dominant IgE targets, with more than 70 to 80% of mite-allergic patients sensitized to them. Because D. farinae and the European dust mite (D. pteronyssinus) share many proteins, IgE responses often cross-react, but the species can still differ in clinical importance depending on where you live.

Why It Matters

Allergic Rhinitis and Year-Round Congestion

Allergic rhinitis is the most common condition this test helps diagnose. In a study of 16,209 patients with allergic rhinitis, dust mite IgE was the most relevant measurement to identify the trigger, with the test's accuracy (a measure of how well it correctly classifies people, called area under the curve) reaching about 0.74 to 0.76 against standard skin testing.

Higher dust mite IgE levels also predict who responds best to allergy shots. In Korean adults with mite-driven allergic rhinitis, those with dust mite IgE levels of 17.5 kU/L or higher had greater odds of clinical remission after subcutaneous immunotherapy.

Asthma Risk

Dust mite IgE is one of the strongest predictors of asthma in children and adolescents. In the PARIS birth cohort study of 714 children, those strongly sensitized to house dust mite (IgE of 3.5 kU/L or higher) had the highest risk of asthma and allergic rhinitis at age 8 to 9. Children with multiple HDM (house dust mite) component sensitizations, especially to both group 1 and group 2 proteins, had the highest asthma rates.

In asthmatic children sensitized to dust mite, blood IgE levels also correlate with eosinophil counts (a type of allergy-related white blood cell) and FeNO (fractional exhaled nitric oxide, a measure of airway inflammation), though they do not predict lung function directly.

Atopic Dermatitis

For people with eczema, dust mite IgE often points to a hidden driver. In a study of patients with atopic dermatitis exposed to high indoor mite levels, component-resolved testing showed that Der p 23 IgE (a D. pteronyssinus protein that often cross-reacts with D. farinae) was strongly linked to severe disease, and Der f 1 and Der f 2 sensitization clustered with the more inflammatory, type 2 dominant form of eczema. In infants under two years old with allergic disease, dust mite IgE positivity grouped with atopic dermatitis, food allergy, and egg white sensitization.

Allergic Conjunctivitis and Comorbid Allergies

In a study of 2,972 children with allergic conjunctivitis, higher serum dust mite IgE predicted having other allergic conditions on top of the eye symptoms. The number tracks the broader load of allergic disease, not just one organ.

What Standard Tests Miss

A general checkup, basic CBC, or even a total IgE level cannot tell you which allergen your body is reacting to. Total IgE reflects overall allergic activity but does not name a culprit. This test pinpoints dust mite specifically, which matters because it is the one major indoor allergen you can systematically reduce with bedding covers, washing, and humidity control, and the one with proven, FDA-cleared immunotherapy options.

Skin prick testing is faster and slightly more sensitive, but blood IgE is more specific for clinically meaningful allergy and works when you cannot stop antihistamines for a skin test, when you have widespread eczema, or when you want a quantitative number to track over time. In one comparison, blood IgE for dust mite reached 71 to 95% specificity for predicting actual airway reactions, depending on the cutoff.

Reference Ranges

There is no universally agreed normal range for D. farinae IgE. Most labs use the traditional cutoff of 0.35 kU/L (kilounits per liter, a measure of antibody concentration), but research increasingly shows that better thresholds exist depending on age and clinical question. The numbers below come from large cohort and immunotherapy studies and should be read as orientation, not as a target. Your lab may use slightly different cutpoints, and a positive result is meaningful only when paired with symptoms.

TierRange (kU/L)What It Suggests
NegativeLess than 0.35No evidence of dust mite sensitization
Low positive0.35 to 1.16Sensitization detectable; clinical relevance depends on symptoms
Moderate positive1.16 to 3.5Optimal cutoff for matching positive skin tests in allergic rhinitis cohort
Strong positive3.5 or higherHighest risk of asthma and allergic rhinitis in childhood cohort data
Very strong17.5 or higherHigher odds of remission with allergy shots in adults

What this means for you: a positive result without symptoms means you are sensitized but not necessarily allergic. A positive result combined with year-round nasal symptoms, asthma, or eczema is much more likely to identify dust mite as a real driver, and the higher the level, the stronger that link tends to be.

Tracking Your Trend

A single dust mite IgE reading tells you whether you are sensitized today. Tracking the number over time tells you something more useful: whether your immune reactivity is rising, falling, or holding steady, and whether the steps you are taking are doing anything.

During allergen immunotherapy, dust mite IgE often rises in the first few months and then declines over years as your immune system shifts toward tolerance. In published immunotherapy cohorts, specific IgE patterns changed predictably with treatment, and in a 3-year retrospective study, mite IgE fell during sustained immunotherapy alongside symptom improvement. In a Chinese SCIT cohort, effective responders showed decreasing dust mite IgE while non-responders showed increases.

For most adults, get a baseline now. If you start immunotherapy or make major changes to your bedroom environment, retest in 6 to 12 months. If your symptoms shift over time, retest annually. The trend matters more than any single number.

What to Do With an Abnormal Result

A positive dust mite IgE result is the start of an investigation, not the end. The next step depends on the level and your symptoms.

  • Pair the number with your symptoms: if you have year-round congestion, sneezing, asthma, or eczema, a positive result strongly supports dust mite as a driver. If you have no symptoms, you are sensitized but may not need treatment.
  • Consider component testing: specialized panels for Der f 1, Der f 2, and Der p 23 can refine your risk and help predict whether immunotherapy is likely to work for you.
  • Test alongside other indoor allergens: cat, dog, mold, and cockroach IgE often co-exist with dust mite sensitization and shape your full environmental picture.
  • See an allergist if levels are high or symptoms are severe: an allergist can order a nasal provocation test, the gold standard for confirming whether dust mite is actually causing your symptoms, and discuss whether allergy shots or under-the-tongue tablets make sense.

When Results Can Be Misleading

A few situations can make a single dust mite IgE reading harder to interpret.

  • Sensitization without disease: about 30% of people with a positive blood IgE for dust mite do not have clinically relevant allergy when tested with nasal provocation. The number alone does not equal a diagnosis.
  • Local allergic rhinitis: some people with classic dust mite symptoms have negative blood IgE but produce IgE locally in the nose. If symptoms strongly suggest dust mite allergy and your blood test is negative, an allergist can test nasal secretions.
  • Corticosteroids: in a small clinical study, oral corticosteroids transiently shifted total IgE levels after the medication was discontinued. If you are on or recently stopped systemic steroids, your numbers may be temporarily off.
  • Aging: in a 20-year follow-up of European adults, dust mite and other allergen sensitization tends to decline after age 20, so older adults may show lower levels than they did in younger years even if symptoms persist.

What Moves This Biomarker

Evidence-backed interventions that affect your Dust Mite (D. Farinae) IgE level

↕ Up & Down
Subcutaneous immunotherapy (allergy shots) for house dust mite
Allergy shots are the first-line treatment that genuinely changes the underlying allergic response. Dust mite IgE typically rises in the first months as your immune system reacts to the controlled exposure, then declines over years as tolerance develops. In a 3-year retrospective study, dust mite IgE fell significantly during sustained immunotherapy alongside symptom improvement. In Chinese SCIT cohorts, effective responders showed decreasing dust mite IgE while non-responders showed increases.
MedicationStrong Evidence
↕ Up & Down
Sublingual immunotherapy (under-the-tongue tablets) for house dust mite
SLIT is a needle-free alternative to allergy shots, with similar effects on the underlying immune response. In preschoolers aged 1 to 4 with perennial allergic rhinitis, dust mite IgE rose at 6 months then returned to baseline at 12 months while protective IgG antibodies increased and symptoms improved. A randomized trial of 1,607 adolescents and adults found a 300-IR (index of reactivity) sublingual tablet was effective and safe for dust-mite-induced allergic rhinitis.
MedicationStrong Evidence
↓ Decrease
Dupilumab (a biologic that blocks type 2 inflammation)
Dupilumab, used to treat moderate-to-severe atopic dermatitis and asthma, suppresses allergen-specific IgE production over time. In a study of 16 patients with allergic rhinitis, dupilumab reduced symptom burden and suppressed allergen-specific IgE production in the nasal lining. A meta-analysis confirmed that dupilumab significantly decreases IgE levels in patients with type 2 inflammatory diseases, with greater effect at higher cumulative doses.
MedicationModerate Evidence

Frequently Asked Questions

References

29 studies
  1. Jeong K, Lee J, Son M, Yi M, Yong T, Shin J, Lee KH, Kim YJ, Park K, Park H, Lee JH, Park JAllergy, Asthma & Immunology Research2015
  2. Batard T, Baron-bodo V, Martelet a, Mignon M, Lemoine P, Jain K, Mariano S, Horiot S, Chabre H, Harwanegg C, Marquette C, Corgier B, Soh WT, Satitsuksanoa P, Jacquet a, Chew F, Nony E, Moingeon PAllergy2016
  3. Hales B, Martin AC, Pearce LJ, Laing I, Hayden C, Goldblatt J, Le Souef PL, Thomas WJournal of Allergy and Clinical Immunology2006
  4. Celi G, Brusca I, Scala E, Villalta D, Pastorello E, Farioli L, Cortellini G, Deleonardi G, Galati P, Losappio L, Manzotti G, Pirovano B, Muratore L, Murzilli F, Cucinelli F, Musarra a, Cilia M, Nucera E, Aruanno a, Ria F, Patria M, Varin E, Polillo BR, Sargentini V, Quercia O, Uasuf CG, Zampogna S, Carollo M, Graci S, Amato S, Mistrello G, Asero RAllergy2019
  5. Yang Y, Zhu R, Huang N, Li W, Zhang W, Wang Y, Yang LAmerican Journal of Rhinology & Allergy2018